Antimicrobial susceptibility of Brucella melitensis isolates from blood samples

Turkish Journal of Medical Sciences

Volumn 38, Issue 3, 2008, Pages 257-262

  Ayaşlioǧlu, Ergin ^a,d   Kiliç, Selçuk ^b   Aydin, Kemalettin ^c   Kiliç, Dilek ^a   Kaygusuz, Sedat ^a   Aǧalar, Canan ^a  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b Refik Saydam Hygiene Center   (Turkey)

^c KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^d NONE   (Turkey)

Author keywords

Azithromycin; Brucellosis; Ciprofloxacin; Rifampin; Streptomycin; Tetracycline

Indexed keywords

BLOOD; HEALTH; PIGMENTS;

ANTIMICROBIAL SUSCEPTIBILITY; AZITHROMYCIN; BLOOD SAMPLES; BRUCELLA; CIPROFLOXACIN (CIPRO); CONVENTIONAL METHODS; MINIMAL INHIBITORY CONCENTRATION (MIC); PUBLIC HEALTH; TEST METHODS; TETRACYCLINE (TC); ZOONOTIC DISEASE;

ANTIBIOTICS;

AZITHROMYCIN; CIPROFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BIOTYPE; BLOOD SAMPLING; BRUCELLA MELITENSIS; CLINICAL ARTICLE; HUMAN; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION;

EID: 45749158167     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia: Churchill Livingstone; 2005. p.2669-74.
2. Celik I, Akbulut HH. Lymphocyte subpopulations in patients with acute brucellosis. Turk J Med Sci 2005; 35: 237-41.
3. Navarro-Martinez A, Solera J, Corredoira J, Beato JL, Martinez-Alfaro E, Atienzar M et al. Epididymoorchitis due to Brucella mellitensis: a retrospective study of 59 patients. Clin Infect Dis 2001; 33: 2017-22.
4. Shapiro DS, Wong JN. Brucella. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of Clinical Microbiology. 7th ed. Washington DC: ASM Press; 1999. p. 625-31.
5. Ayaslioglu E, Tekeli E, Birengel S. Significant elevation of serum soluble CD14 levels in patients with brucellosis. Jpn J Infect Dis 2005; 58: 11-4.
6. Akova M, Gur D, Livermore DM, Kocagoz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother 1999; 43: 1298-1300.
7. Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs 1997; 53: 245-56.
8. Corbel MJ. Microbiological aspects. In: Madkour MM, editor. Madkour's Brucellosis. 2nd ed. Berlin Heidelberg New York: Springer-Verlag; 2001. p.51-64.
9. Kose S, Kilic S, Ozbel Y. Identification of Brucella species isolated from proven brucellosis patients in Izmir, Turkey. J Basic Microbiol 2005; 45: 323-7.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 15th Informational Supplement. CLSI Document M 100-S15, Wayne, PA: USA, 2005.
11. Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003; 35: 337-8.
12. Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004; 23: 405-7.
13. Sengoz G, Yasar KK, Kutlu SB, Durdu YB, Ozdemir R, Nazlican O. E-test susceptibility results of Brucella strains for streptomycin, rifampicin, ciprofloxacin and tetracycline. Mikrobiyol Bul 2006; 40: 265-8.
14. Yamazhan T, Aydemir S, Tunger A, Serter D, Gokengin D. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey. Med Princ Pract 2005; 14: 413-6.
15. Turkmani A, Ioannidis A, Christidou A, Psaroulaki A, Loukaides F, Tselentis Y. In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob 2006; 5:24.
16. Madkour MM. Treatment. In: Madkour MM, editor. Madkour's Brucellosis. 2nd edn. Berlin Heidelberg New York: Springer-Verlag; 2001. p.241-61.
17. Gur D, Kocagoz S, Akova M, Unal S: Comparison of E test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob Agents Chemother 1999; 43: 2337.
18. Hall WH. Modern chemotherapy for brucellosis in humans. Rev Infect Dis 1990; 12: 1060-99.
19. Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents 2005; 26: 101-5.
20. Ariza J, Gudiol F, Pallares R, Viladrich PF, Rufi G, Corredoira J, Miravitlles MR. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 1992; 117: 25-30.
21. Garcia-Rodriguez JA, Garcia Sanchez JE, Trujillano I, Garcia Sanchez E, Garcia Garcia MI, Fresnadillo MJ. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob Agents Chemother 1995; 39: 1194-5.
22. Doganay M, Aygen B. Use of ciprofloxacin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis 1992; 11: 74-5.
23. Lang R, Raz R, Sacks T, Shapiro M. Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis. J Antimicrob Chemother 1990; 26: 841-6.
24. Agalar C, Usubutun S, Turkyilmaz R. Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis 1999; 18: 535-8.
25. Akova M, Uzun O, Akalin E, Hayran M, Unal S, Gur D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 1993; 37: 1831-1834.
26. Saltoglu N, Tasova Y, Inal AS, Seki T, Aksu HS. Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med J 2002; 23: 921-924.
27. Kalo T, Novi S, Nushi A, Dedja S. Ciprofloxacin plus doxycycline versus rifampicin plus doxycycline in the treatment of acute brucellosis.Med Mal Infect 1996; 26: 587-9.
28. Karabay O, Sencan I, Kayas D, Sahin I. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial. BMC Infect Dis 2004; 4: 18.
29. Solera J, Beato JL, Martinez-Alfaro E, Segura JC, de Tomas E; Grupo de Estudio de Castilla la Mancha de Enfermedades Infecciosas Group. Azithromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin Infect Dis 2001; 3: 506-9.
30. Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, Orrantia-Gradin R, Hernandez-Oliva GM, Gutierrez-Rubio AT et al. Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis 2004; 36: 636-8.